VIDO scientists strengthen mpox preparedness
VIDO scientists have recieved >$1-million in total funding to study mpox (formerly known as monkeypox) from the Canadian Institutes of Health Research “Team Grant: Mpox (monkeypox) and zoonotic threats.”
VIDO scientists have recieved >$1-million in total funding to study mpox (formerly known as monkeypox) from the Canadian Institutes of Health Research “Team Grant: Mpox (monkeypox) and zoonotic threats.”
An adjuvant developed by VIDO and partners is a key component in a vaccine to protect koalas from chlamydia. The adjuvant improves the effectiveness of the vaccine by improving the koala immune response.
VIDO and the Vaccine Formulation Institute (VFI) sign collaborative research agreement to help drive joint vaccine development and support a rapid and unified response to future pandemics.